IDEAYA Biosciences, Inc. Increase (Decrease) in Contract with Customer, Asset
IDEAYA Biosciences, Inc. (IDYA) reported Increase (Decrease) in Contract with Customer, Asset of $9.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-08-04
- 2026-06-30: Increase (Decrease) in Contract with Customer, Asset 6 month $9.45M.
- 2025-06-30: Increase (Decrease) in Contract with Customer, Asset 6 month $0.00.
| Period end | Increase (Decrease) in Contract with Customer, Asset 6 month |
|---|---|
| 2026-06-30 | $9.45M 10-Q · filed 2026-08-04 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |